Completes Patient Enrollment in Phase II Osteoporosis Prevention Trial Will Present Full Data Set on Phase III ORACAL Treatment Trial at ASBMR Closes Additional Tranche of a Financing That Has Raised a Total of $24.5 Million PHILADELPHIA, PA – July 12, 2011 —Tarsa Therapeutics today reported progress in its two ongoing clinical development programs for its [...]
Positive, Statistically Significant Top-Line Results Support Proceeding to NDA Submission in 2011 Trial Conducted in Accordance with Special Protocol Assessment with FDA Full Results to Be Presented in Peer-Reviewed Forum Later this Year PHILADELPHIA, PA – March 24, 2011 —Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in [...]
Completes Patient Dosing in ORACAL Trial; Results Expected in Early Spring Enrollment Opened in New Phase II Postmenopausal Osteoporosis Prevention Trial PHILADELPHIA, PA – February 14, 2011 — Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company’s once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from [...]
Philadelphia, PA, Boonton, NJ and Brussels, Belgium – September 24, 2010—Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. (OTCBB: UGNE) today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis. The data are being presented at the 2010 Osteoarthritis Research Society International [...]
—Completes Patient Enrollment in Global, Randomized, Double-Blind Phase III Trial— —Receives Positive Safety Reports from Two Separate Reviews by Independent Data Monitoring Committee— PHILADELPHIA, PA – July 22, 2010 — Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient [...]
New Company Established by Unigene and Three Leading Venture Capital Firms Launched with $24 Million Series A Financing BOONTON, NJ and PHILADELPHIA, PA – October 20, 2009 — Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed [...]
Conference Call Wednesday, October 21st, 9:00 AM EDT BOONTON, N.J.--(BUSINESS WIRE)--Oct. 20, 2009-- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will host a conference video call on Wednesday, October 21, 2009, at 9:00 AM EDT to update investors on the Company's recently announced agreement to license Unigene's Phase III oral calcitonin program to Tarsa Therapeutics. Unigene [...]
